Cuprina Receives Nasdaq Noncompliance Notice Due to Bid Price Below $1
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 28 2025
0mins
Source: Newsfilter
- Stock Price Warning: Cuprina Holdings received a noncompliance notice from Nasdaq due to its closing bid price failing to meet the $1 minimum requirement over the last 30 trading days, indicating significant market pressure on the company.
- Compliance Period: The company has a 180-day compliance period to regain its bid price, and if it achieves a closing price of at least $1 for ten consecutive days, it can avoid delisting, highlighting the urgency for Cuprina to act swiftly to ensure continued listing.
- Potential Consequences: If compliance is not regained within the specified timeframe, Cuprina may need to consider measures such as a reverse stock split to meet Nasdaq's other listing standards, reflecting the company's vulnerability in the capital markets.
- Ongoing Trading: Despite the warning, Cuprina's shares will continue to trade, indicating that the market remains cautious yet hopeful about the company's efforts to regain compliance in the future.
Analyst Views on CUPR
About CUPR
Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company, which is engaged in the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. It manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. It has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
